BAY 948862
Sponsors
Bayer AG
Conditions
Chronic kidney diseaseProteinuriaTreatment of children with chronic kidney disease and proteinuria
Phase 3
(19920) A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weightadjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria
RecruitingCTIS2023-504884-17-00
Start: 2022-02-04Target: 253Updated: 2025-11-24
(20186 - FIONA OLE) An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria
RecruitingCTIS2023-504885-50-00
Start: 2022-11-07Target: 69Updated: 2025-11-25